Express Press Release Distribution

Accounting
Advertising
Aerospace
Agriculture
Apparel & Fashion
Automotive
Biotech
Chemicals
Computers
Construction
Consumer Services
Defense
Education
Electronics
Energy
Entertainment
Environment
Financial
Food & Beverage
Government
Healthcare
Human Resources
Industrial
International Trade
Internet & Online
Law
Management
Marketing
Media
Non Profit
Pharmaceuticals
Real Estate
Retail
Semiconductors
Small Business
Software
Sports
Telecommunications
Transportation / Logistics
Travel

EPR Archived News

Archived News 2012
~ April
~ March
~ February
~ January

Archived News 2011
~ December
~ November
~ October
~ September
~ August
~ July
~ June
~ May
~ April
~ March
~ February
~ January

Archived News 2010
Archived News 2009
Archived News 2008
Archived News 2007
Archived News 2006
Archived News 2005
Archived News 2004

 

Clinical Trials at UK done by Veeda Clinical research

Released on = March 14, 2006, 12:50 am

Press Release Author = jameswatt

Industry = Healthcare

Press Release Summary = veeda cr offers services of phase I/II Clinical trials at
UK and india.

Press Release Body = The 15 billion dollar world of Clinical Research has a major
new player in its
fastest growing sector, that of phase I clinical trials. Veeda Clinical
Research(www.veedacr.com),
known as Veeda CR, brings together the highly respected UK CRO Phase 1 CTU
Ltd, ClinSearch Labs Pvt. Ltd. of Ahmedabad and Triphasic Clinical Trials
Laboratories a Plymouth, UK based, GLP accredited laboratory.
Veeda CR can count many of the world's top ten Pharmaceutical Companies as
clients and sees huge potential in unleashing the synergies of its Indian -
European collaboration onto a global market place. Veeda CR's revenue in India
currently stands at 32 crores and is expected to double over the next 12 months.
"Veeda CR represents the ideal bridge between cultures - combining vast
experience and expertise in handling the most technically complex trials to the
most stringent regulatory standards with the massive technical, data
management and volunteer capability of the Indian subcontinent" said Director


Mr. Apurva Shah.


Veeda CR sees its key attribute as its uncompromising commitment to quality
and it will use the recognised expertise of its European personnel to help train its
research professionals in India. This will be achieved by a two way traffic
between continents with research professionals from India undergoing intensive
training in the UK and Western project management skills following European
research projects into India.

Dr Kiran Marthak, a Director of Veeda CR, is delighted to have joined the Veeda
CR at this exciting juncture. Dr Marthak is a pioneer of clinical research activities
in India and brings to Veeda CR experience of working with pharmaceutical
majors such as Novartis, German Remedies, Pfizer, and Ranbaxy.
Dr Marthak said "We have managed to combine the best of a top 5 Early Clinical
Development Unit in the UK, with all the advantages of a vibrant new unit on the
Indian subcontinent, with both Units operating to exactly the same stringent
standards set by international regulatory authorities"
Veeda CR has adopted the image of the Bengal Tiger to exemplify its promise to
"Unleash the power of India". Maurice Cross, a Director of Veeda CR's said "our
marketing team was searching for an icon that represented the power, strength
and integrity of Veeda and was also indigenous to the Indian sub continent. Our
research gave us a number of interesting alternatives but the dignity and
overwhelming presence of the Bengal Tiger fit the bill perfectly. When we saw the
photograph it simply swept us away, both our UK and Indian colleagues were
unanimous in their enthusiasm for it. We understand Veeda means "knowledge"
and our tiger exudes knowledge and wisdom from every pore. It is a wonderful
symbol of both India and Veeda CR."


© 2006 Veeda Clinical Research(www.veedacr.com)


Web Site = http://www.veedacr.com

Contact Details = jameswatt
new street new road
5545444
seo@bitscape.co.in

  • Printer Friendly Format
  • Back to previous page...
  • Back to home page...
  • Submit your press releases...
  •